Akebia Therapeutics (AKBA) vs Spruce Biosciences (SPRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Spruce Biosciences (SPRB) has outperformed Akebia Therapeutics (AKBA) over the past year, losing 63.8% versus a loss of 75.1%. Over five years, AKBA leads with a -85.6% price change compared with -99.8% for SPRB. Spruce Biosciences is the larger company by market cap ($109.2 million vs $107.0 million), about 1.0 times the size, while Akebia Therapeutics is growing revenue faster (+47.5% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | SPRB |
|---|---|---|
| Share price | $0.3855 | $38.00 |
| Market cap | $107.04M | $109.21M |
| 1-day change | -8.71% | -6.15% |
| YTD return | -76.06% | -56.38% |
| 1-year return | -75.13% | -63.81% |
| 5-year return | -85.56% | -99.75% |
| Forward P/E | — | 11.79 |
| EPS (TTM) | $-0.17 | $-33.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $236.20M | $0 |
| Revenue growth (YoY) | +47.46% | -100.00% |
| Net income (latest FY) | $-5.34M | $-38.97M |
| Gross margin | 83.29% | — |
| Operating margin | 9.95% | — |
| Net margin | -2.26% | — |
| 52-week high | $1.73 | $111.00 |
| 52-week low | $0.361 | $38.00 |
| Distance from 52-week high | -77.72% | -65.77% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +678.21% | +288.00% |
| Average volume | 8.05M | 89.33K |
| Shares outstanding | 277.66M | 2.87M |
| Employees | 194 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SPRB has outperformed AKBA by 11.3 percentage points over the past year.
- Akebia Therapeutics grew revenue faster in its latest fiscal year (+47.46% vs -100.00%).
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Spruce Biosciences
SPRB stock →Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
AKBA vs SPRB FAQ
Which is bigger, Akebia Therapeutics or Spruce Biosciences?
Spruce Biosciences (SPRB) is larger, with a market capitalization of $109.21M compared with $107.04M for Akebia Therapeutics (AKBA).
Which stock has performed better over the past year, AKBA or SPRB?
SPRB returned -63.81% over the past 12 months, compared with -75.13% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and Spruce Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.